Zinc Sulfate (Zinc Sulfate) Patent Expiration, LOE Window & CMS Spending

Zinc Sulfate (Zinc Sulfate) by Daiichi Sankyo: Off-Patent Genericized (AB Competition), 5 AB generics, $9.0M 2024 CMS Part D & Medicaid spend, and $1,100 CA SB 17 specialty launch WAC.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorDaiichi Sankyo
FDA Application & PathwayN209377 (NDA)
Exclusivity / Cliff HorizonOff-Patent Genericized (AB Competition)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity DateNot listed / N/A
Orange Book Patents (*PED Extensions)0 patents (0 *PED)
Active AB-Rated Generic Competitors5
2024 CMS Total Public Spend$9.0M
2024 Medicare Part D Spend$0
2024 Medicaid Spend$9.0M
Reported Wholesale Price Change (CA SB 17)Specialty launch notice ($1,100 intro WAC)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Daiichi Sankyo across sibling Meru public-data platforms.